Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3745406 | 0.88 | KDM1A (0.42) | KMT2AHPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8218294 | 0.86 | LMNA (0.46) | KMT2AHPGDCYP1A2CYP2C19LMNA | |
| SCHEMBL3753774 | 0.85 | RORB (0.40) | KMT2ACYP1A2BLM | |
| SCHEMBL3752842 | 0.81 | ALDH1A1 (0.40) | KMT2AHPGDLMNAADRB2SMN1; SMN2 | |
| SCHEMBL3751995 | 0.81 | SCN9A (0.44) | KMT2AHPGDCYP2C19SMN1; SMN2SCN9A | |
| SCHEMBL12427716 | 0.80 | F2RL3 (0.40) | KMT2AHPGDSMN1; SMN2ACP1 | |
| SCHEMBL3747547 | 0.80 | MEN1 (0.40) | KMT2AHPGDCYP1A2CYP2C19LMNA | |
| SCHEMBL3752590 | 0.80 | KMO (0.38) | KMT2AHPGDLMNAADRB2SMN1; SMN2 | |
| SCHEMBL3753486 | 0.79 | XDH (0.41) | HPGDCYP1A2CYP3A4CYP2C19SCN9A | |
| SCHEMBL3752506 | 0.79 | L3MBTL1 (0.46) | KMT2AHPGDCYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-11-25 | — | — | US | disclosed |
| WO-2008031501-A2 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298221-A1 | 2-PHENOXY NICOTINE ACID DERIVATIVE AND USE THEREOF | NAPRT, PNPO, FABP3 | KMT2A 1678/4885HPGD 347/4885CYP1A2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.